药品详细
Flurbiprofen (氟比洛芬 )
化学结构式图
中文名
氟比洛芬
英文名
Flurbiprofen
分子式
Not Available
化学名
2-(3-fluoro-4-phenylphenyl)propanoic acid
分子量
Average: 244.2609
Monoisotopic: 244.089957865
Monoisotopic: 244.089957865
CAS号
5104-49-4
ATC分类
M01A 未知;M02A 未知;S01B 抗炎药
药物类型
small molecule
阶段
商品名
Adfeed;Ansaid (Pfizer);Antadys;Apo-Flurbiprofen;Cebutid;Flurbiprofen Axetil;Flurofen;Froben;Froben Sr;Novo-Flurprofen;Nu-Flurbiprofen;Ocufen;Stayban;Zepolas;
同义名
FLP;Flurbiprofen Sodium;Flurbiprofene [INN-French];Flurbiprofeno [INN-Spanish];Flurbiprofenum [INN-Latin];
基本介绍
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
生产厂家
- Allergan pharmaceutical
- Bausch and lomb inc
- Caraco pharmaceutical laboratories ltd
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Mylan pharmaceuticals inc
- Pharmacia and upjohn co
- Pliva inc
- Sandoz inc
- Teva pharmaceuticals usa inc
- Theragen inc
封装厂家
参考
| Synthesis Reference | Not Available |
| General Reference | Not Available |
剂型
| Form | Route | Strength |
|---|---|---|
| Solution / drops | Ophthalmic | 0.03% |
| Tablet, film coated | Oral | 100 mg |
| Tablet, film coated | Oral | 50 mg |
规格
| Unit description | Cost | Unit |
|---|---|---|
| Ocufen 0.03% Solution 2.5ml Bottle | 22.7 USD | bottle |
| Flurbiprofen powder | 20.9 USD | g |
| Flurbiprofen Sodium 0.03% Solution 2.5ml Bottle | 15.99 USD | bottle |
| Ocufen 0.03% eye drops | 10.63 USD | ml |
| Flurbiprofen 0.03% eye drop | 4.37 USD | ml |
| Ansaid 100 mg tablet | 2.1 USD | tablet |
| Flurbiprofen 100 mg tablet | 1.08 USD | tablet |
| Flurbiprofen 50 mg tablet | 0.8 USD | tablet |
| Ansaid 50 mg Tablet | 0.58 USD | tablet |
| Apo-Flurbiprofen 100 mg Tablet | 0.37 USD | tablet |
| Novo-Flurprofen 100 mg Tablet | 0.37 USD | tablet |
| Nu-Flurbiprofen 100 mg Tablet | 0.37 USD | tablet |
| Apo-Flurbiprofen 50 mg Tablet | 0.27 USD | tablet |
| Novo-Flurprofen 50 mg Tablet | 0.27 USD | tablet |
| Nu-Flurbiprofen 50 mg Tablet | 0.27 USD | tablet |
化合物类型
| Type | small molecule |
| Classes |
|
| Substructures |
|
适应症
ANTIINFLAMMATORY AND ANTIRHEUMATIC 消炎抗风湿;
药理
| Indication | Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis. | |||||||||||||||||||||||||||||||||||
| Pharmacodynamics | Flurbiprofen, a nonsteroidal anti-inflammatory agent (NSAIA) of the propionic acid class, is structually and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen, and has similar pharmacological actions to other prototypica NSAIAs. Flurbiprofen exhibits antiinflammatory, analgesic, and antipyretic activities. The commercially available flurbiprofen is a racemic mixture of (+)S- and (-) R-enantiomers. The S-enantiomer appears to possess most of the anti-inflammatory, while both enantiomers may possess analgesic activity. | |||||||||||||||||||||||||||||||||||
| Mechanism of action | Similar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity. | |||||||||||||||||||||||||||||||||||
| Absorption | Fluribiprofen is rapidly and almost completely absorbed following oral administration. Peak plasma concentrations are reached 0.5 - 4 hours after oral administration. | |||||||||||||||||||||||||||||||||||
| Volume of distribution |
|
|||||||||||||||||||||||||||||||||||
| Protein binding | > 99% bound, primarily to albumin. Binds to a different primary binding site on albumin than anticoagulants, sulfonamides and phenytoin. | |||||||||||||||||||||||||||||||||||
| Metabolism |
Hepatic. Cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite, 4’-hydroxy-flurbiprofen. The 4’-hydroxy-flurbiprofen metabolite showed little anti-inflammatory activity in animal models of inflammation.
|
|||||||||||||||||||||||||||||||||||
| Route of elimination | Flurbiprofen is poorly excreted into human milk. Following dosing with flurbiprofen, less than 3% of flurbiprofen is excreted unchanged in the urine, with about 70% of the dose eliminated in the urine as parent drug and metabolites. Renal elimination is a significant pathway of elimination of flurbiprofen metabolites. | |||||||||||||||||||||||||||||||||||
| Half life | R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours | |||||||||||||||||||||||||||||||||||
| Clearance | Not Available | |||||||||||||||||||||||||||||||||||
| Toxicity | LD50=10 mg/kg (orally in dogs).
Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of flurbiprofen. Flurbiprofen may increase blood pressure and/or cause fluid retention and edema. Use caution in patients with fluid retention or heart failure. Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Anaphylactoid and serious skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) may occur. Common adverse events include abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI bleeding, GI perforation, nausea, peptic ulcer, vomiting, renal function abnormalities, anemia, dizziness, edema, liver function test abnormalities, headache, prolonged bleeding time, pruritus, rash, tinnitus. |
|||||||||||||||||||||||||||||||||||
| Affected organisms |
|
|||||||||||||||||||||||||||||||||||
| Pathways | Not Available |
理化性质
| Properties | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| State | solid | ||||||||||||||||||||||||||||||||||||
| Melting point | 110-111 oC | ||||||||||||||||||||||||||||||||||||
| Experimental Properties |
|
||||||||||||||||||||||||||||||||||||
| Predicted Properties |
|
||||||||||||||||||||||||||||||||||||
药物相互作用
| Drug | Interaction |
|---|---|
| Acenocoumarol | The NSAID, flurbiprofen, may increase the anticoagulant effect of acenocoumarol. |
| Alendronate | Increased risk of gastric toxicity |
| Anisindione | The NSAID, flurbiprofen, may increase the anticoagulant effect anisindione. |
| Cyclosporine | Monitor for nephrotoxicity |
| Dicumarol | The NSAID, flurbiprofen, may increase the anticoagulant effect of dicumarol. |
| Ginkgo biloba | Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided. |
| Methotrexate | The NSAID, flurbiprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity. |
| Tamoxifen | Flurbiprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Flurbiprofen is initiated, discontinued or dose changed. |
| Telmisartan | Concomitant use of Telmisartan and Flurbiprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. |
| Timolol | The NSAID, Flurbiprofen, may antagonize the antihypertensive effect of Timolol. |
| Tolbutamide | Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Flurbiprofen is initiated, discontinued or dose changed. |
| Torasemide | Flurbiprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Flurbiprofen is initiated, discontinued or dose changed. |
| Trandolapril | The NSAID, Flurbiprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Flurbiprofen is initiated, discontinued or dose changed. |
| Treprostinil | The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Flurbiprofen. Monitor for increased bleeding during concomitant thearpy. |
| Trimethoprim | The strong CYP2C9 inhibitor, Flurbiprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Flurbiprofen is initiated, discontinued or dose changed. |
| Voriconazole | Flurbiprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if flurbiprofen is initiated, discontinued or dose changed. |
| Warfarin | Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of flurbiprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if flurbiprofen is initiated, discontinued or dose changed. |
食物相互作用
- Avoid alcohol.
- Take with food to reduce gastric irritation.
收藏